secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001437749-25-031466
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava appoints Dawn Bir to board; plans simufilam TSC-epilepsy study in H1 2026
--------------------------------------------------------------------------------

- Dawn Bir appointed as Class I director effective Oct 21, 2025; board expanded to eight members.
- Bir is a seasoned biopharma executive with prior roles at Reata, Geron, Soleno, and Pharmacyclics.
- Company plans to initiate first clinical study for simufilam in TSC-related epilepsy in first half of 2026.
- Bir eligible for standard non-employee director compensation; no material interests or arrangements disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/0001437749-25-031466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925031466/sava20251020_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer